Vynamic®
Inizio Advisory

Navigating Turbulence and Transformation

2025 Health Industry Outlook

2025

- Innovating with Precision
- Life Sciences in 2025
- Health/Med Tech in 2025
- Health Services in 2025
- Leveraging Innovation for Growth or Transformative Trends Shaping the Med Device Industry in 2025
- Evolving Models, Expanding Opportunities

www.vynamic.com

Click here to get started

The health industry in 2025 is at a critical juncture, navigating a turbulent landscape shaped by economic pressures, shifting regulatory frameworks, and rapid technological advancements. Set against a backdrop of global challenges such as aging populations, rising chronic disease burdens, and geopolitical uncertainties, the industry is undergoing profound transformation. Encompassing Life Sciences, Health Services and Health Tech, the industry faces persistent headwinds. Inflationary pressures, supply chain disruptions, and workforce shortages continue to challenge resilience, while the Inflation Reduction Act (IRA) ramps up introducing sweeping changes to drug pricing and reimbursement dynamics. Adding to this complexity is a new U.S. administration poised to reshape healthcare priorities, potentially redefining access, equity, and cost structures.

Amid this uncertainty, significant opportunities are emerging. Advances in artificial intelligence (AI) are transforming care delivery, enabling more precise diagnostics, personalized treatment plans, and streamlined operations. Meanwhile, groundbreaking therapeutic innovations, such as cell and gene therapies and RNA-based treatments, offer the potential to tackle some of the most challenging medical conditions. However, these advancements also introduce new complexities: increased regulatory scrutiny, heightened cybersecurity risks, and the pressing need for robust infrastructure to support the adoption of these technologies. Against this backdrop of transformation and challenge, a closer look at the sector-specific outlooks reveals how Life Sciences, Health Services, and MedTech are uniquely positioned to navigate the complexities of 2025 while capitalizing on emerging opportunities.

Life Sciences in 2025:
Innovating with Precision

The Life Sciences sector continues to push the boundaries of medical science. However, it must navigate a complex landscape shaped by policy changes, the rapid advancement of technology, and increasing demands for measurable value. Success in this environment requires balancing innovation with scalability, addressing cost pressures while ensuring equitable access to care.

Navigating New Economics: The Inflation Reduction Act

The Inflation Reduction Act (IRA) introduces landmark changes in drug pricing and reimbursement, forcing companies to reevaluate their market access strategies. With Medicare negotiating drug prices and capping out-of-pocket costs, the industry faces tighter margins. These changes, expected to save the U.S. government $288 billion by 2031 while reducing pharmaceutical revenues by $75 billion by 2030[1], underscore the urgency of adapting to a new pricing environment. For Commercial leaders, these shifts require innovative pricing strategies and earlier alignment with payers and regulators to sustain market competitiveness.

The IRA is redefining the economics of product launches, requiring organizations to navigate tighter margins and accelerated timelines. Companies must shift focus to integrating real-world evidence (RWE) earlier in the lifecycle and designing launch strategies that prioritize payer engagement. Time to peak revenue will depend on the ability to demonstrate clear value to stakeholders in the context of Medicare pricing caps and private payer spillover effects. Proactively aligning cross-functional teams and embedding data-driven insights into launch frameworks will ensure competitive readiness in this rapidly evolving landscape.

Advancing with AI and Data-Driven Strategies

A large pharmaceutical company's Data Science & AI team was looking for support to develop and scale their internal AI platform engine to power customer insights, precision engagement, and multi-channel execution for commercial and medical teams.

The Result: Vynamic helped develop the operating model for demand planning, resource allocation, intake, and change management. By aligning stakeholders and proposing new operating models, the new office was able to rapidly expand and leverage the base that had been built for new generative and predictive AI solutions.

As regulatory challenges reshape the landscape, AI is emerging as a powerful driver of innovation and efficiency in Life Sciences. Companies leveraging AI have reported a 20% reduction in R&D timelines[2], improved trial design, and accelerated patient recruitment. Commercially, AI has driven a 30% improvement in sales forecasting accuracy[3] and a 20% increase in marketing ROI.[4] AI offers unmatched efficiency and precision, making it a critical enabler for success in a competitive, cost-sensitive market. The real potential lies in integrating AI across the value chain, turning fragmented data into actionable insights that drive innovation, precision, and scalability. Companies that embed AI into decision-making processes, from trial design to commercial strategy, will not only accelerate time-to-market but also create tailored, outcome-driven solutions for patients and stakeholders. Leaders who treat AI as a strategic capability rather than a stand-alone solution will reshape the trajectory of healthcare innovation, setting new benchmarks for efficiency and impact.

Breakthrough Therapies and Scalable Delivery

Advanced therapies—cell and gene therapies, RNA treatments, and radiopharmaceuticals—are ushering in a new era of medicine. With a projected compound annual growth rate of 25% for gene therapies through 2027, these treatments hold promise for previously intractable conditions.[5] However, the high costs and complex manufacturing processes present significant challenges for widespread adoption. Commercial leaders must integrate scalable delivery frameworks into strategic planning to address manufacturing complexity and costs, embedding payer engagement, provider education, and patient access early in the lifecycle. Leveraging real-world evidence (RWE) and data platforms will be critical to demonstrating value and securing buy-in. Organizations that adopt flexible operating models and invest in precision manufacturing will balance innovation with affordability, forging partnerships to bridge access gaps and drive lasting impact across the healthcare ecosystem.

Building Resilience in Life Sciences Supply Chains

Supply chain vulnerabilities remain a pressing concern for Life Sciences organizations. Over 80% of active pharmaceutical ingredients (APIs) used in the U.S. are sourced from overseas[6], leaving the industry exposed to disruptions caused by geopolitical tensions, natural disasters, and economic instability. Drug shortages have increased by 45% over the past five years[7], underscoring the urgent need for a more robust and localized supply chain framework. For Commercial leaders, enhancing supply chain resilience is critical to maintaining operational stability and ensuring patient access to essential medications. A resilient supply chain is foundational to operational success and patient care. Organizations that proactively address vulnerabilities and adopt innovative strategies will safeguard continuity while building trust across their stakeholder networks. The supply chain's role in supporting innovation extends to the rapid and efficient launch of new products.

Smarter, Faster Product Launches

A global pharmaceutical company's launch team defines an overall vision that tied back to a shared purpose and core values.

The Result: Vynamic helped our client 1) Develop clear, user-friendly framework that was easily accessible and shared via an online platform 2) Built a launch foundation based on existing frameworks and extensive stakeholder input/feedback and 3) Created a resource bank of launch templates and guidance documents.

Digital-first product launches are becoming the norm, enabling companies to reduce costs while increasing market reach. By 2025, 50% of launches will leverage omnichannel strategies[8], driven by real-time analytics. Efficient launches accelerate adoption and create competitive advantages in an environment where speed-to-market is critical. Digital-first launches empower organizations to act swiftly and adapt to market conditions, ensuring broader impact and reach. Companies that embrace these strategies will define the future of product commercialization. The transformation of product launches is complemented by evolving direct-to-consumer pharmacy models, which enhance access and engagement.

Product launches have evolved into dynamic, omnichannel efforts requiring precision, agility, and seamless execution. Success lies in aligning strategy with execution, using digital-first frameworks and real-time adaptability to sustain momentum in a competitive market. Agility across the launch process—driven by robust data platforms, real-world evidence, and predictive analytics— enables organizations to prioritize stakeholders, refine engagement, and optimize resources. By fostering cross-functional collaboration and integrating real-time feedback, companies can accelerate adoption, expand reach, and set new benchmarks for commercialization excellence.

Pharmacy 2.0 Transforming Access with Direct-to-Consumer Models

DTC pharmacy models, projected to grow to $206 billion in 2025[9], are reshaping the healthcare landscape by placing patients at the center of their care journey. Success in this space requires more than operational efficiency—it demands a strategic alignment of digital tools, patient engagement, and seamless integration into broader healthcare ecosystems. Organizations that leverage data to personalize interactions, predict patient needs, and enhance medication adherence will redefine patient loyalty and satisfaction.

The real opportunity lies in connecting DTC models with value-based care strategies, ensuring these platforms not only improve access but also deliver measurable health outcomes. By fostering collaborations with payers and providers, companies can expand their reach while addressing critical gaps in chronic disease management and preventive care. Leaders who embrace these models strategically will not only differentiate their offerings but also elevate their role in delivering more equitable, accessible healthcare solutions.

Partnering for Success with IDN-Focused Go-to-Market Strategies

With 60% of U.S. hospitals now part of IDNs[10], these consolidated networks wield significant influence over drug purchasing and utilization, driving the adoption of value-based care models. IDN-focused go-to-market models achieve a 15% higher market access success rate[11], highlighting the importance of customized engagement strategies in navigating IDN complexities. By 2025, 85% of life sciences companies expect IDNs to control drug purchasing, underscoring the need for tailored go-to-market (GTM) strategies that align with IDNs' focus on cost efficiency, collaborative partnerships, and real-world evidence.[12] As IDNs continue to consolidate their purchasing power, life sciences companies must evolve their go-to-market (GTM) strategies to align with these networks' priorities. Success requires a deep understanding of IDN segmentation to tailor strategies that address the unique needs of different networks, whether they prioritize cost efficiency, clinical outcomes, or population health. By aligning operating models with IDN priorities, companies can create scalable frameworks that ensure consistency while allowing for customization at the local level.

Actionable Opportunities for Life Sciences

As the Life Sciences sector navigates a rapidly evolving landscape, leaders must adopt strategies that address current challenges while leveraging AI and innovation to position their organizations for sustainable growth. Below are a starting point of actionable opportunities to guide this transformation:

Redesign Operating Models for Agility: Adapt structures to respond to regulatory shifts and market dynamics. Use AI to optimize workflows, streamline decision-making, and scale operations efficiently.

Enhance Customer Engagement with Personalization: Leverage data, AI and digital to deliver tailored interactions for providers, payers, and patients, building trust and improving access to complex therapies.

Embrace AI-Powered Strategic Planning: Use predictive analytics and scenario planning to anticipate disruptions, refine go-to-market strategies, and improve launch readiness.

Revolutionize Product Launches: Adopt digital-first, data-driven launch models powered by AI for precise targeting, real-time feedback, and seamless cross-functional collaboration.

Integrate data-driven Metrics into Commercial Strategies: Use AI to track and measure product performance in real-world settings, aligning commercial efforts with measurable outcomes that resonate with stakeholders.

Driving the Future of Life Sciences and Beyond

The Life Sciences sector stands at the forefront of healthcare innovation, blending advanced technologies, patient-centric strategies, and operational excellence to address pressing global challenges. Success requires balancing scalable solutions for breakthrough therapies, ensuring supply chain resilience, and embracing digital-first approaches to enhance access and efficiency. By focusing on these priorities, Life Sciences organizations are not only shaping the future of medicine but also laying the foundation for broader transformation across the healthcare ecosystem. As innovation accelerates, the interplay between Life Sciences and Health Services becomes increasingly critical, creating opportunities to redefine care delivery and patient outcomes

Health Services in 2025: Evolving Models, Expanding Opportunities

The Health Services sector in 2025 is navigating a profound transformation driven by rising costs, advancing technologies, and shifting patient expectations. Healthcare organizations are striving to balance operational efficiency with patient-centered approaches while embracing innovations that reimagine traditional care delivery models. These changes demand strategic integration of virtual care, digital health, personalized medicine, pharmacy evolution, and artificial intelligence (AI).

Maximizing Potential with AI-Driven Efficiency

AI is projected to reduce U.S. healthcare costs by $150 billion annually by 2026[13], with applications ranging from diagnostics to administrative automation. AI-driven diagnostic tools have achieved up to 99% accuracy in identifying diseases like liver and kidney conditions[14], while predictive analytics help organizations anticipate patient needs, optimize resource allocation, and reduce hospital readmissions.[15] To maximize AI's potential, Health Services organizations must prioritize integration strategies, workforce training, and governance frameworks that align AI initiatives with broader organizational goals.

AI empowers Health Services to operate more efficiently while delivering high-quality, patient-focused care. Organizations that invest in AI strategically will redefine care delivery and drive measurable improvements. As AI enhances operational efficiency, digital health platforms are empowering patients and providers with actionable insights for personalized care.

Empowering Patients and Providers Through Digital Health

A 40,000+ employee Academic Medical Center (AMC) with several hospital sites, dozens of ambulatory facilities, and multiple call center entities had an obsolete way of working model for patient engagement. The Digital Engagement leadership team realized through the millions of interactions with patients that they had created barriers to health services causing a digital divide, and a widening gap in access to and utilization of digital healthcare.

The Result: Vynamic partnered with the senior leaders at the AMC on a system-centric approach to the way they engage with patients and organization structure to codify their why, enhance coordination on engagement, and create consistent and standard approaches to the way the team interacted on each and every connection point along the patient journey.

In 2025, health systems are expected to spend $30 billion on interoperability solutions to enable seamless data sharing across platforms. Tools like wearable health monitors and fitness apps empower patients to actively manage their health while providing clinicians with real-time, actionable insights.[16] The widespread adoption of these technologies, evidenced by 672 million health and fitness app downloads in 2024[17], underscores their growing role in patient care. To fully realize their potential, organizations must invest in secure, interoperable data systems.

Digital health technologies are enhancing provider-patient relationships and transforming healthcare into a more interactive and data-driven experience. Strengthening these platforms will further expand access and foster collaboration. Building on the advancements of digital health, virtual care provides scalable solutions for improved accessibility and continuity of care.

Expanding Reach through Scalable Virtual Care

Virtual care has become an essential component of healthcare delivery, addressing gaps in access and improving continuity of care. With telehealth usage growing by over 20% annually, virtual care is expanding into specialties like behavioral health, chronic disease management, and post-surgical care.[18] Virtual models bridge access gaps for underserved populations while offering cost-effective solutions for managing complex conditions. However, widespread adoption requires robust IT infrastructure, tailored reimbursement models, and efforts to build patient trust through clear communication and onboarding. Virtual care enhances accessibility and provides continuity for patients, particularly in underserved areas. Organizations that optimize their virtual care offerings will strengthen their impact across healthcare delivery. As virtual care grows, the integration of personalized medicine is redefining tailored treatments and improving outcomes.

Closing Gaps to Improve Care Accessibility

"We have most assuredly NOT kept up our operating models and governance structure. We deliver different experiences to the same customer / patient depending on what silo or 'product' they're engaging with us."

– Health System Executive

Care accessibility remains a critical focus in 2025 as organizations work to close disparities in underserved populations. Investments in community-based health hubs, telehealth expansion, and mobile health units are bridging the gap for vulnerable groups. Retail pharmacies are also stepping into larger roles, providing preventive care services such as immunizations and health screenings. These initiatives are essential as the healthcare system strives to meet the needs of aging populations and those in rural areas. As organizations strive to enhance care accessibility and meet the needs of underserved populations, pharmacies are emerging as pivotal players in the healthcare ecosystem, evolving from traditional dispensing roles into comprehensive, patient-centric hubs that drive prevention, chronic disease management, and care coordination.

Transforming Pharmacies into Patient-Centric Hubs

> *"With physician shortages and increasing demand, we see an evolving role for pharmacy to address patient needs through medical and pharmacy solutions…we are with patients daily and need to figure this out."*
>
> **– VP, Pharmacy Channel Services, Health System**

Pharmacies are transforming into integral hubs for healthcare delivery, playing a key role in chronic disease management, preventive care, and tele pharmacy. The specialty drug market, projected to account for 60% of U.S. drug spending by 2025[19], highlights the critical importance of pharmacies in modern healthcare. Automation adoption, expected to grow by 8% annually through 2026, is enabling faster dispensing, reducing operational errors, and enhancing efficiency.[20] Strategic investments in expanded services and technology will further integrate pharmacies into care coordination efforts. Pharmacies are evolving into patient-centric hubs, supporting holistic healthcare delivery. Their expanded role is integral to the future of coordinated and accessible care.

Actionable Opportunities:

To thrive in 2025, Health Services leaders must embrace innovations in AI, digital health, virtual care, and employ greater accessibility strategies and approaches.

Providers

Leverage AI and predictive analytics to optimize resource allocation, improve clinical decision-making, and identify high-risk patients for tailored interventions. Integrate wearable data into EHR systems to enable personalized care and expand telehealth workflows to scale virtual care for chronic conditions. Prioritize strategic planning and mobilization to modernize operating models, aligning them with patient-centered care delivery while ensuring seamless data integration across platforms.

Health Plans

Use AI-driven insights to design proactive engagement strategies that address unmet member needs and drive improved outcomes. Develop personalized digital experiences and align reimbursement models with value-based care, emphasizing prevention and chronic care management. Invest in data interoperability to improve population health coordination and mobilize cross-functional teams to reimagine product offerings with a member-centric focus.

Pharmacies

Pharmacies are evolving into critical healthcare hubs by leveraging AI for predictive inventory management, enhancing specialty drug capabilities, and integrating with provider and payer systems to streamline care coordination. Hospitals and health system pharmacies can adopt advanced automation and specialty services to improve operational efficiency while supporting chronic care management. By embracing value-based packaging of pharmacist-led health services—such as medication adherence programs and preventive care—pharmacies can align with new operating models and go-to-market strategies that emphasize outcomes and patient-centric solutions. Investing in digital platforms, direct-to-consumer models, and workforce upskilling ensures pharmacies meet evolving demands while expanding their impact across the healthcare ecosystem.

By strategically integrating these innovations, Health Services organizations can reduce costs, expand access, and enhance outcomes. Success will depend on collaboration and leveraging technology to deliver value-based care and drive impactful change across the healthcare ecosystem.

Health/Med Tech in 2025:
Leveraging Innovation for Growth or Transformative Trends Shaping the Med Device Industry in 2025

The Med Device industry in 2025 is at a pivotal moment, driven by rapid advancements in technology, evolving regulatory landscapes, and shifting healthcare priorities. To stay competitive, Med Device leaders must adapt to trends that emphasize personalization, connectivity, value-based care, sustainability, and compliance, reshaping the future of innovation and patient care.

Integrating AI for Precision and Scalability

AI's role in MedTech is transforming diagnostics, workflows, and personalized treatment options, aligning with precision-focused advancements in Life Sciences. AI-driven diagnostic tools, achieving up to 99% accuracy in disease identification, are enabling MedTech companies to support more precise clinical decision-making.[21] For MedTech leaders, AI offers opportunities to deliver scalable solutions that enhance operational efficiency, improve outcomes, and meet the growing demand for measurable value in healthcare. AI is a transformative enabler for MedTech, driving precision at scale while fostering deeper collaborations with Life Sciences organizations to advance patient-centric care.

By leveraging AI as a strategic capability rather than a stand-alone tool, organizations can transform their go-to-market approaches, accelerate product adoption, and build stronger partnerships across the healthcare ecosystem. Those who embed AI into their operating models will not only optimize performance but also redefine the future of MedTech by advancing patient-centric innovation.

Adapting to Regulatory Shifts and Value-Based Care Priorities

As value-based care models gain prominence, MedTech leaders face the dual challenge of designing devices that align with both regulatory compliance and economic and clinical needs. With 85% of life sciences companies expecting IDNs to control drug purchasing by 2025, the shift toward centralized decision-making underscores the importance of prioritizing value.[22] For MedTech leaders, this presents a critical opportunity to develop solutions that demonstrate measurable outcomes, enhance cost-efficiency, and align with the priorities of healthcare providers and payers. Companies that strategically align their offerings with the economic and clinical goals of value-based care will strengthen market access and navigate regulatory complexity effectively.

Scaling Advanced Therapies with Device Innovation

The rise of advanced therapies, such as cell and gene treatments in Life Sciences, underscores the need for MedTech devices capable of supporting precise administration, monitoring, and scalability. With gene therapies projected to grow at a 25% CAGR through 2027[23], the demand for robust infrastructure to enable scalable adoption is rapidly increasing. MedTech leaders have a pivotal opportunity to develop innovative delivery systems that enhance the accessibility and effectiveness of these transformative therapies. By developing devices that ensure the scalability of advanced therapies, focusing on precision delivery, real-time monitoring, and seamless integration into provider workflows, MedTech leaders can bridge innovation and accessibility. Collaborating with Life Sciences and leveraging real-world data will enhance device functionality and patient outcomes. By adopting agile models and patient-centric design, organizations can accelerate therapy adoption, reduce access barriers, and solidify their role in transformative healthcare.

Revolutionizing Care with Remote Patient Monitoring

Remote patient monitoring, projected to grow from $53.6 billion in 2022 to $175.2 billion by 2027,[24] is transforming healthcare by enabling real-time monitoring and proactive intervention for chronic conditions, post-operative care, and aging in place. MedTech leaders must develop integrated solutions that seamlessly connect devices, software, and workflows, ensuring actionable data and intuitive, patient-centric features to enhance engagement and adherence.

Strategic partnerships with providers and payers are essential to align remote patient monitoring with value-based care, demonstrating outcomes like reduced hospital readmissions and optimized resource allocation. By leveraging analytics and focusing on measurable impact, organizations can establish remote patient monitoring as a cornerstone of future healthcare.

Accelerating Adoption with Digital-First Product Launches

Digital-first product launches are becoming essential for MedTech as organizations aim to maximize market reach and accelerate adoption. By 2025, 50% of product launches are expected to use omnichannel strategies, enabling broader engagement and faster adoption. Leveraging omnichannel platforms and real-time analytics allows MedTech leaders to connect with stakeholders more effectively, personalize outreach, and scale innovations more rapidly.[25] These strategies empower organizations to adapt to market dynamics, accelerate product adoption, and gain competitive advantages in a fast-paced healthcare environment.

Actionable Opportunities:

To thrive in 2025, MedTech leaders must integrate innovation, navigate regulatory complexity, and adapt their strategies to align with evolving market demands. Below are seven key actionable opportunities that incorporate AI, personalization, and strategic adaptation.

Redesign Operating Models for Agility:
Adapt structures to respond to regulatory shifts and market dynamics. Use AI to optimize workflows, streamline decision-making, and scale operations efficiently.

Innovate Devices for Advanced Therapies:
Develop precise delivery and monitoring devices for cell and gene treatments, aligning functionality with value-based care and reimbursement models.

Embrace Digital-First Launch Strategies:
Use omnichannel platforms to personalize campaigns and adapt launches to better engage providers, payers, and patients.

Enhance Customer Experience (CXT):
Build seamless customer journeys with user-friendly devices, real-time feedback, and transparent communication that meets stakeholder needs.

Align Strategic Planning Across Teams:
Unify R&D, regulatory, and commercial strategies to ensure cohesive execution of product launches and market goals.

Conclusion

To navigate the complexities of 2025, organizations across Life Sciences, Health Services, and Health Tech must focus on three key pillars:

Operational Resilience:
Strengthen supply chains, enhance workforce adaptability, and invest in technologies that support continuity.

Technological Integration:
Leverage AI, blockchain, and interoperability solutions to streamline operations and deliver personalized experiences.

Collaborative Innovation:
Foster partnerships across sectors to align on value-based models, equitable access, and regulatory compliance.

By aligning these strategies with patient-centric and data-driven approaches, leaders can drive sustainable growth while addressing the evolving demands of the healthcare ecosystem. The coming year demands more than endurance—it requires bold leadership, strategic adaptability, and collaboration across sectors. As the health industry navigates this pivotal moment, success will depend on balancing innovation with cost control, ensuring equitable access, and embracing the transformative potential of technology while meeting the demands of a shifting political and economic environment.

To continue the conversation, ***contact Vynamic*** for your strategic planning needs.

Sources

1. Congressional Budget Office. (2021). [Estimated budgetary effects of H.R. 5376, the Build Back Better Act, as passed by the House of Representatives](#) on November 19, 2021.

2. Financial Times. (n.d.). [Artificial intelligence is significantly enhancing pharmaceutical R&D](#).

3. Associated Press. (n.d.). [AI facilitates the analysis of extensive datasets, expediting drug discovery processes.](#)

4. Nature. (2024). [AI optimizes study design and patient recruitment in clinical trials. Nature.](#)

5. Market.us. (n.d.). [Gene therapy market size to reach USD 49.3 billion by 2032 with a CAGR of 25%.](#)

6. U.S. Government Accountability Office. (2019). [Drug Safety: FDA Has Improved Its Foreign Drug Inspection Program, but Needs to Assess the Effectiveness and Staffing of Its Foreign Offices.](#)

7. Advisory Board. (2023, March 24). ['People's lives are at stake': Drug shortages reach a 5-year high.](#)

8. Scayle. (n.d.). [Omnichannel retail trends for 2025: Shaping the future of engagement.](#)

9. Fortune Business Insights. (n.d.). [U.S. pharmacy market size, share, trends & forecast [2020–2028].](#)

10. Definitive Healthcare. (2023, April). [How many IDNs are in the U.S.?](#)

11. Trinity Life Sciences. (2023, June). [Integrated Delivery Networks (IDNs).](#)

12. WLH Consulting. (2024, September). [Adapting to IDN Consolidation: Implementing New Account Management Strategies for 2025.](#)

13. Accenture. (2017). [Artificial intelligence: Healthcare's new nervous system.](#)

14. Bian, J., & Topaloglu, U. (2024). Enhancing diagnostic precision in liver lesion analysis using a deep learning approach. [Nature Reviews Clinical Oncology](#), 21(5), 345-356.

15. McAlister, F. A., & Padwal, R. S. (2022). Effective hospital readmission prediction models using machine-learned patient phenotypes. [BMC Health Services Research](#), 22(1), 1415.

16. Statista. (2024, November 9). [Future spending on health interoperability in the U.S.](#)

17. Datavant. (2022, May 10). [What is Interoperability in Healthcare and Why is it Important?](#)

18. American Medical Association. (2021). [2021 Telehealth Survey Report.](#)

19. Mercer. (2023). [2024 Drug Trend and Pipeline Report.](#)

20. Grand View Research. (2023). [Pharmacy Automation Devices Market Size Report, 2030.](#)

21. Bidollahkhani, M., Atasoy, F., Abedini, E., Davar, A., Hamza, O., Sefaoğlu, F., Jafari, A., Yalçın, M. N., & Abdellatef, H. (2023). GENIE-NF-AI: Identifying Neurofibromatosis Tumors using Liquid Neural Network (LTC) trained on AACR GENIE Datasets. arXiv.

22. Definitive Healthcare. (2024, June 12). How to Approach IDNs in Pharma and Biotech.

23. Market.us. (2024). Gene Therapy Market Size, Share, Forecast | CAGR Of 25%.

24. VCDoctor. (2023, May 15). Remote Patient Monitoring Market Growth, Trends, and Forecast 2022-2027.

25. Interakt. (2024, November 30). Key Omnichannel Trends to Watch in 2025.

Vynamic®
Inizio Advisory

Vynamic, an Inizio Advisory company, is a leading management consulting partner to global health organizations. Our purpose is simple: We believe there is a better way. We are passionate about shaping the future of health, and for more than 20 years we've helped clients transform by connecting strategy to action. Through a structured, yet flexible delivery model, our accomplished leaders work as an extension of client teams, enabling growth, performance, and culture.